Top Ten most popular articles on Pharmafile.com this week
It’s Friday, and it’s time for another rundown of our most popular articles with our readers this week.
Besides a swathe of approvals and drug access stories breaking this week, recruitment and staffing in the pharma industry was particularly eventful, with industry giants Pfizer and GSK making big moves on an executive level.
However, the most popular piece this week relates to one of the biggest stories of the year – the relocation of the European Medicines Agency headquarters following its exodus from London as a result of Brexit.With 19 EU member states fighting it out to become the next home of the agency, we spoke to four of the contenders to discover the offers on the table.
The ultimate decision is due to be revealed next week, so be sure to check pharmafile.com then for all the coverage of the news as it happens.
Check out the week’s ten most popular articles on Pharmafile.com now!
Roche’s Ocrevus received a positive recommendation from the Committee for Medical Products for Human Use (CHMP) in the treatment of active relapsing forms of multiple sclerosis.
Transparency is becoming important across a whole range of industries but, for the pharmaceutical industry, it can mean life or death. Ben Hargreaves examines the push for more clinical trial data to be revealed so that research can continue to move forward and to stop unfavourable results becoming lost.
The CAR-T space has progressed rapidly over the last few years, culminating in FDA approvals for Novartis and Gilead to treat B-cell lymphomas; however, work conducted by Autolus has potentially opened a new therapeutic pathway for the treatment of T-cell lymphoma.
Pfizer has promoted Albert Bourla to the role of Chief Operating Officer in order to allow Chief Executive Officer Ian Read to focus his efforts on long-term strategy and government and industry liaison and deal-making.
NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both multiple sclerosis and breast cancer, it has emerged.
Sanofi has decided to build its pipeline in neurological disorders with the agreement to develop Principia Biopharma’s BTK inhibitor candidate for multiple sclerosis in a deal worth $40 million upfront with a further $765 million lying in-wait.
Swedish biopharma firm Hansa Medical broke tragic and unexpected news in November when it announced the death of its CEO Göran Arvidson following his short time with the company.
Boehringer Ingelheim has announced that Cyltezo, its biosimilar of Abbvie’s Humira, has received marketing authorisation approval from the European Commission, confirming that is comparable in safety and efficacy to its originator product.
GSK, under its new CEO, has made most of its waves recently not with approvals but with high-profile appointments, and it continued in this trend with the appointment Hal Barron.
With the result of the Brexit referendum, the future of the EMA’s London headquarters was cast in doubt. Now, 19 EU member states are bidding to become the new home of the agency.
COVID-19 news has slowed down in the last week, allowing different pharma developments to take …
As the year winds to a close, excitement is rising around the efficacy and availability …